Showing results (551-560 of 672) with videos related to
Sort By:
Pageof 68
Antimicrobial Agents and Chemotherapy|December 25, 2003
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patientsRobin Wood, Keikawus Arasteh, Hans-Jürgen Stellbrink, et al.Plos One|September 13, 2012
T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384Todd Hulgan, Gregory K Robbins, Spyros A Kalams, et al.Plos One|October 19, 2012
Identifying conservation successes, failures and future opportunities; assessing recovery potential of wild ungulates and tigers in Eastern CambodiaHannah J O'Kelly, Tom D Evans, Emma J Stokes, et al.AIDS (London, England)|May 29, 2004
Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12Beverly E Sha, Michelle Onorato, John A Bartlett, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 26, 1999
Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3R B Pollard, D Peterson, D Hardy, et al.AIDS (London, England)|November 2, 2005
Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individualsHaydar Kuekrek, Tobias Schlingmann, Hernan Valdez, et al.Journal of Climate|August 4, 2020
Spectrally Dependent CLARREO Infrared Spectrometer Calibration Requirement for Climate Change DetectionXu Liu, Wan Wu, Bruce A Wielicki, et al.Disease Markers|October 24, 2001
ANX7 as a bio-marker in prostate and breast cancer progressionM Srivastava, L Bubendorf, L Nolan, et al.The Journal of Infectious Diseases|July 7, 2000
In vivo antagonism with zidovudine plus stavudine combination therapyD V Havlir, C Tierney, G H Friedland, et al.AIDS Research and Human Retroviruses|September 25, 2012
Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activationJulia M Shaw, Peter W Hunt, J William Critchfield, et al.Pageof 68